Figure 4

MPT0E028/erlotinib co-treatment induces acetylated histone and non-histone proteins and upregulates apoptotic proteins in lung adenocarcinoma cells. (a) Effect of erlotinib/MPT0E028 co-treatment on drug-induced DNA fragmentation in A549 cells. Cells were treated with the indicated concentrations of MPT0E028 and/or erlotinib for 72 h, and DNA fragmentation was quantitatively measured using a cell death detection ELISA kit. Columns, mean (n=4); bars, S.D. Symbols: *P<0.05; **P<0.01; and ***P<0.001 compared with the control group. (b and c) Western blot analysis of γH2AX, caspase 3, and PARP in CL97 (b) and PC9/IR (c) cells. Cells were treated with MPT0E028 and/or erlotinib for 72 h and cell lysates were subjected to immunoblotting using the indicated antibodies. (d and e) Comparison of co-treatment with erlotinib plus MPT0E028 (d) or SAHA (e) in A549 cells. Cells were treated with the indicated drugs for 72 h, and cell lysates were subjected to immunoblotting using the indicated antibodies